Status:
UNKNOWN
Autologous Bone Marrow Concentrate in Elective Tranforaminal Lumbar Interbody Fusion Surgery
Lead Sponsor:
Pei-Yuan Lee, MD
Collaborating Sponsors:
Aeon Biotechnology Corporation
Conditions:
Bone Marrow
Spinal Fusion
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
This study aims to evaluate the effect of bone marrow concentration on bone healing and spinal fusion by comparing clinical and imaging outcomes between patients receiving transforaminal lumbar intebo...
Detailed Description
Spinal arthrodesis has become the mainstay of treatment for severe spinal deformity, spinal instability, spondylolisthesis, and symptomatic degenerative disease. Its primary goal is to develop an osse...
Eligibility Criteria
Inclusion
- With indication of transforaminal lumbar decomprassion and interbody fusion, ex. spondylolisthesis, symptomatic degenerative disease, spinal instability.
- Involved levels between T12 and S1
- Involved levels less than three levels
- Age between 20 and 70 years
Exclusion
- With prior history of spinal surgery
- With current or prior history of tumor, trauma or infection at spine
- With current diagnosis of coagulopathy
- With current or prior history of cancer
- With current or prior history of hematological disease
- Pregnancy
- Patients who will not cooperate with one-year followup
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03793530
Start Date
August 1 2017
End Date
December 1 2020
Last Update
April 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Show Chwan Memorial Hospital
Changhua, Changhua, Taiwan, 500